{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:59:13Z","timestamp":1793066353821,"version":"4.5.0"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,9,21]]},"abstract":"<jats:p>\n            Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono, an enoyl-acyl carrier protein reductase (FabI) inhibitor, and is a first-in-class antibiotic with a novel mode of action to specifically target fatty acid synthesis in\n            <jats:italic>Staphylococcus<\/jats:italic>\n            spp. The efficacy, safety, and tolerability of afabicin were compared with those of vancomycin\/linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI) due to staphylococci in this multicenter, parallel-group, double-blind, and double-dummy phase 2 study.\n          <\/jats:p>","DOI":"10.1128\/aac.00250-20","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T13:37:39Z","timestamp":1596548259000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":69,"title":["Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin\/Linezolid"],"prefix":"10.1128","volume":"64","author":[{"given":"Frederick","family":"Wittke","sequence":"first","affiliation":[{"name":"Debiopharm International SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vincent","sequence":"additional","affiliation":[{"name":"Debiopharm International SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chen","sequence":"additional","affiliation":[{"name":"Southbay Pharma Research, Buena Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Heller","sequence":"additional","affiliation":[{"name":"Long Beach Clinical Trials, Long Beach, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Kabler","sequence":"additional","affiliation":[{"name":"Sunrise Hospital and Medical Center, Las Vegas, Nevada, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Overcash","sequence":"additional","affiliation":[{"name":"eStudySite, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Leylavergne","sequence":"additional","affiliation":[{"name":"Debiopharm International SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8319-4079","authenticated-orcid":false,"given":"Guenna\u00eblle","family":"Dieppois","sequence":"additional","affiliation":[{"name":"Debiopharm International SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1198-743X(16)30095-7"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu444"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0764-7"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002769"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041870"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004744"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky530"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humic.2018.08.005"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72333"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-3-237"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep08131"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1039\/C7MD00528H"},{"key":"e_1_3_2_15_2","unstructured":"Menetrey Tacheron A Wittke F Grossmann M Fuhr R Etter AL Nicolas V Hussaini A. 2017. IV and oral drug development of the staphylococcal-specific antibiotic Debio 1450: results from formulation finding and multiple ascending dose studies poster P1337. Abstr 27th Eur Congr Clin Microbiol Infect Dis Vienna Austria."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01741-15"},{"key":"e_1_3_2_17_2","unstructured":"FDA. 2013. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. https:\/\/www.fda.gov\/files\/drugs\/published\/Acute-Bacterial-Skin-and-Skin-Structure-Infections---Developing-Drugs-for-Treatment.pdf. Accessed May 2019."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05738-11"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02580-17"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix987"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70737-6"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.241"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx329"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/2049936117723228"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw118"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw274"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy165"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-8-42"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268816002855"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy720"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Kuehn J Wittke F Barbier M Le Fresne S Carton T Leuillet S Le Vacon F Vuagniaux G. 2016. The staphylococcal-specific antibiotic Debio 1450 minimizes disturbance to the gut microbiota in mice poster P2244. Abstr IDWeek New Orleans LA.","DOI":"10.1093\/ofid\/ofw172.1792"},{"key":"e_1_3_2_32_2","unstructured":"Nowakowska J Kuehn J Vincent C Wittke F Le Fresne-Languille S Carton T Leuillet S Le Vacon F Vuagniaux G. 2018. Staphylococcal-selective antibiotic afabicin preserves the human gut microbiota poster P0281. 28th ECCMID Madrid Spain."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.4155\/cli.13.65"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02515-16"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12944"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0358"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01669-18"},{"key":"e_1_3_2_38_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_39_2","volume-title":"Performance standards for antimicrobial susceptibility testing, 27th ed","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. Performance standards for antimicrobial susceptibility testing, 27th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00250-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00250-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:33:33Z","timestamp":1645486413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00250-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9,21]]}},"alternative-id":["10.1128\/AAC.00250-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00250-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"2020-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00250-20"}}